Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Alphamab Oncology ( (HK:9966) ) is now available.
Alphamab Oncology has announced a technology development collaboration with Suzhou Alphamab, a connected transaction under the Hong Kong Stock Exchange rules. This agreement involves Suzhou Alphamab providing technology development services for Alphamab’s bispecific antibody-drug conjugate candidate, including developing production processes and preparing samples for regulatory filings. The partnership is valued at RMB10,240,000 and is expected to enhance Alphamab’s capabilities in bringing new cancer treatments to market, potentially strengthening its position in the biopharmaceutical industry.
More about Alphamab Oncology
Alphamab Oncology is a biopharmaceutical company based in the Cayman Islands, specializing in the development of innovative cancer therapies. The company’s primary focus is on antibody-drug conjugates (ADCs), which are designed to target and treat various forms of cancer.
Average Trading Volume: 4,322,104
Technical Sentiment Signal: Buy
Current Market Cap: HK$8.86B
Find detailed analytics on 9966 stock on TipRanks’ Stock Analysis page.